BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/28/2025 10:45:13 AM | Browse: 24 | Download: 44
 |
Received |
|
2024-09-24 23:29 |
|
Peer-Review Started |
|
2024-10-09 01:18 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-12-20 11:57 |
|
Revised |
|
2024-12-21 09:06 |
|
Second Decision |
|
2025-01-14 03:32 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-01-14 06:39 |
|
Articles in Press |
|
2025-01-14 06:39 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-21 03:55 |
|
Publish the Manuscript Online |
|
2025-02-28 10:45 |
| ISSN |
1948-9358 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Abul Bashar Mohammad Kamrul-Hasan, Joseph M Pappachan, Deep Dutta, Lakshmi Nagendra, Mohammad Shafi Kuchay and Nitin Kapoor |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph M Pappachan, MD, Professor, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in |
| Key Words |
Tirzepatide; Drug adherence; Study drug discontinuation; Adverse events; Withdrawal by the study subjects |
| Core Tip |
The reasons for permanent discontinuation of tirzepatide vs controls (placebo, insulin, and glucagon-like peptide-1 receptor agonists [GLP-1RAs]) are not systematically assessed based on data from randomized controlled trials. We studied 17 randomized controlled trials (n = 14645) and found that the risks of study drug discontinuation were greater with higher doses of tirzepatide than with insulin or GLP-1RAs. Tirzepatide, at all doses, had higher risks of adverse event-related discontinuation than insulin. Such risks were only greater with higher doses of tirzepatide than with placebo or GLP-1RAs. Discontinuation risk due to withdrawal by the study subjects was lower with tirzepatide than with placebo or insulin. |
| Publish Date |
2025-02-28 10:45 |
| Citation |
<p>Kamrul-Hasan ABM, Pappachan JM, Dutta D, Nagendra L, Kuchay MS, Kapoor N. Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis. <i>World J Diabetes</i> 2025; 16(4): 101731</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i4/101731.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i4.101731 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
